domenica 31 maggio 2020

FDA Approves New Option to Treat Heavy Menstrual Bleeding Associated with Fibroids in Women - Oriahnn (an estrogen and progestin combination product consisting of elagolix, estradiol and norethindrone acetate)

Fonte: FDA Food and Drug Administration

Link all'articolo completo